Показать сокращенную информацию
Progression-free survival (PFS) in primary advanced or recurrent endometrial cancer (pA/rEC) in the overall and mismatch repair proficient (MMR/MSS) populations and in histological and molecular subgroups: Results from part 2 of the RUBY trial
dc.contributor.author | Mirza, M. | |
dc.contributor.author | Ghamande, Sh. | |
dc.contributor.author | Hanker, L. Ch. | |
dc.contributor.author | Black, D. | |
dc.contributor.author | Raascou-Jensen, N. | |
dc.contributor.author | Gilbert, L. | |
dc.contributor.author | Oaknin, A. | |
dc.contributor.author | Secord, A. A. | |
dc.contributor.author | Savarese, A. | |
dc.contributor.author | Holloway, R. W. | |
dc.contributor.author | Kristeleit, R. | |
dc.contributor.author | Buscema, J. | |
dc.contributor.author | Boere, I. A. | |
dc.contributor.author | Sharma, S. | |
dc.contributor.author | Gennigens, Ch. | |
dc.contributor.author | Ghatage, P. | |
dc.contributor.author | Yablons, K. | |
dc.contributor.author | Stevens, S. | |
dc.contributor.author | Trukhan, H. | |
dc.contributor.author | Powell, M. | |
dc.date.accessioned | 2025-03-06T07:50:15Z | |
dc.date.available | 2025-03-06T07:50:15Z | |
dc.date.issued | 2024 | |
dc.identifier.uri | https://rep.bsmu.by/handle/BSMU/47502 | |
dc.description | Progression-free survival (PFS) in primary advanced or recurrent endometrial cancer (pA/rEC) in the overall and mismatch repair proficient (MMR/MSS) populations and in histological and molecular subgroups: Results from part 2 of the RUBY trial / M. Mirza, Sh. Ghamande, L. Ch. Hanker [et al.] // ESMO Open. – 2024. – Vol. 9, suppl. 5. – Art. 103538. – URL: https://www.esmoopen.com/action/showPdf?pii=S2059-7029%2824%2901307-3 (date of access: 04.03.2025). | ru_RU |
dc.description.abstract | Background: In Part 1 of the phase 3 RUBY trial (NCT03981796) in pA/rEC, patients (pts) receiving dostarlimab (dostar)/carboplatin-paclitaxel (CP) exhibited significant benets in PFS and overall survival versus CP alone. Outcomes may be further improved by adding a poly(ADP-ribose) polymerase inhibitor (PARPi). Here we report results from Part 2 of RUBY of dostar/CP followed by dostar/niraparib (nira; a PARPi) maintenance therapy in pts with pA/rEC. Methods: Pts were randomized 2:1 to dostar 500 mg IV + CP Q3W for 6 cycles followed by dostar 1000 mg IV Q6W + nira (individualized starting dose of 200 or 300 mg) PO daily for 3 years from randomization or to placebo (PBO) + CP Q3W for 6 cycles followed by PBOs for 3 years. The primary endpoint was PFS in the overall and MMRp/MSS populations. Results: 291 pts were randomized (192 dostar/CP + dostar/nira; 99 PBO/CP). PFS was significantly improved in pts receiving dostar/CP + dostar/nira vs PBO/CP in the overall and MMRp/MSS populations (Table). In pts with endometrioid carcinoma, pts with other histologies, and across most biomarker subgroups (eg, TP53mut), the hazard ratio (HR) directionally favored dostar/CP + dostar/nira in the overall and MMRp/MSS populations. The safety pro fi le observed was consistent with those of the individual agents. | ru_RU |
dc.language.iso | en | ru_RU |
dc.title | Progression-free survival (PFS) in primary advanced or recurrent endometrial cancer (pA/rEC) in the overall and mismatch repair proficient (MMR/MSS) populations and in histological and molecular subgroups: Results from part 2 of the RUBY trial | ru_RU |
dc.type | Article | ru_RU |